Evogene (EVGN) Other Non-Current Liabilities (2012 - 2025)
Evogene (EVGN) posted Other Non-Current Liabilities of $3.1 million for Q4 2025, down 28.18% sequentially from $4.3 million in Q2 2025, and down 28.98% YoY from $4.3 million in Q4 2024.
Evogene (EVGN) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Evogene has reported Other Non-Current Liabilities for 12 years, with the latest figure at $3.1 million in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 28.98% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 28.98% YoY) and the FY2025 annual result came in at $3.1 million, down 28.98% from the prior year.
- Other Non-Current Liabilities declined to $3.1 million in Q4 2025 per EVGN's latest filing, from $4.3 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $4.7 million in Q4 2022 and troughed at $3.1 million in Q4 2025.
- A 5-year average of $4.2 million and a median of $4.3 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities gained 16.59% in 2021, then fell 28.98% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $4.3 million in 2021, then gained by 8.31% to $4.7 million in 2022, then dropped by 5.12% to $4.4 million in 2023, then retreated by 2.24% to $4.3 million in 2024, then dropped by 28.98% to $3.1 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.1 million, $4.3 million, and $4.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.07 Mn |
| Jun 30, 2025 | 4.28 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Jun 30, 2024 | 4.25 Mn |
| Dec 31, 2023 | 4.43 Mn |
| Jun 30, 2023 | 4.34 Mn |
| Dec 31, 2022 | 4.67 Mn |
| Jun 30, 2022 | 4.36 Mn |
| Dec 31, 2021 | 4.31 Mn |
| Dec 31, 2020 | 3.69 Mn |
| Jun 30, 2020 | 3.52 Mn |
| Dec 31, 2019 | 3.33 Mn |
| Dec 31, 2018 | 2.90 Mn |
| Dec 31, 2017 | 3.44 Mn |
| Dec 31, 2016 | 3.30 Mn |
| Sep 30, 2013 | -7.76 Mn |
| Jun 30, 2013 | -7.76 Mn |
| Dec 31, 2012 | -7.76 Mn |